• Explore /
  • Poster
  • / ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.

ASCENT-05/OptimICE-RD (AFT-65): Phase 3, randomized, open-label study of adjuvant sacituzumab govitecan (SG) + pembrolizumab (pembro) vs pembro ± capecitabine (cape) in patients (pts) with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant therapy (NAT) and surgery.

Abstract Poster

Authors

null

Sara M. Tolaney

Dana-Farber Cancer Institute, Boston, MA

Sara M. Tolaney , Angela DeMichele , Toshimi Takano , Hope S. Rugo , Charles Perou , Otto Metzger , Heather Anne Parsons , Cesar Augusto Santa-Maria , Gabrielle Betty Rocque , Wenliang Yao , Shawn W. Sun , Simonetta Mocci , Ann H. Partridge , Lisa A. Carey

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Adjuvant Therapy

Clinical Trial Registration Number

NCT05633654

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS619)

DOI

10.1200/JCO.2023.41.16_suppl.TPS619

Abstract #

TPS619

Poster Bd #

447a

Abstract Disclosures

Similar Posters

First Author: Daniel Olson

First Author: David B. Page

First Author: Ana Christina Garrido-Castro

First Author: Joyce O'Shaughnessy